A total of 516 patients with advanced NSCLC and a PD-L1 TPS greater than or equal to 50% who received first-line pembrolizumab monotherapy at four academic centers in the United States and had a minimum follow-up of 36 months were included in the retrospective cohort. Here, CD274 is linked to non-small cell lung carcinoma.